Prevalence of High Risk Obstructive Sleep Apnoea by Berlin Questionnaire in Patients with Hypertension: Study from a Tertiary Care Hospital

Ozaifa Kareem
University of Kashmir

Masood Tanvir
Government Medical College Srinagar

Ghulam Nabi Bader (gnbader@kashmiruniversity.ac.in)
University of Kashmir
https://orcid.org/0000-0002-6820-0805

Research

Keywords: Obstructive Sleep Apnoea, hypertension, Berlin Questionnaire, Epworth Sleepiness Scale

DOI: https://doi.org/10.21203/rs.3.rs-50792/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

**Background:** Obstructive Sleep Apnoea (OSA), a condition characterized by a complete or partial cessation of airflow during sleep, can cause various cardiovascular disorders including hypertension. The aim of the study was to determine the prevalence of OSA in patients with hypertension.

**Methods:** A cross-sectional prospective cohort study of 504 patients with hypertension was undertaken at a tertiary care hospital of India for a period of six months. OSA was evaluated using the Berlin questionnaire while the daytime sleepiness was determined using Epworth Sleepiness Scale. Data analysis was done using SPSS v. 20.

**Results:** High risk of OSA was identified in 120 (23.8%) patients and the prevalence of sleepiness (Epworth Sleepiness score ≥16) was found to be 32.5% (95% CI, p<0.001) in these patients. The mean neck circumference, waist circumference and waist-to-hip ratio for high-risk OSA group were 37.41 ± 3.396 cm, 105.90 ± 11.28 cm and 1.01 ± 0.065 respectively while for the low-risk group, these parameters were 35.45 ± 2.652 cm, 98.75 ± 10.87 cm and 0.99 ± 0.080 respectively (95% CI, p<0.001). The mean blood pressure (BP) ≥133.52/84.37 mm Hg was recorded in patients with a high risk of OSA (95% CI, P<0.05), and resistant hypertension (3.3%) was significantly associated with the risk of OSA (95% CI, P<0.05).

**Conclusion:** In the tertiary health care setting, the prevalence of high-risk of OSA in patients with hypertension is high. Screening for OSA should be a part of the hypertensive medical investigation and patients may benefit from a proper evaluation of OSA.

Background

Obstructive Sleep Apnoea (OSA) is a sleep-related breathing disorder that involves complete or partial cessations in airflow due to the collapse of the upper airway, despite an ongoing effort to breathe (Guilleminault et al., 2004). The obstruction of the upper airway occurs because of the inadequate motor tone of the tongue and/or airway dilator muscles, (Park, et al., 2011) that is associated with fragmented sleep pattern, arousals from sleep and fall in oxygen saturation (Grace et al., 2015). Nocturnal oxygen desaturations cause sympathetic surges conducive to the development of acute cardiovascular events (i.e., stroke, myocardial infarction, and nocturnal sudden death) and chronic conditions such as systemic hypertension, coronary artery disease, and heart failure (Bradley 2003; Leung et al., 2001; Peppard et al., 2000). Hypertension is an important public health challenge worldwide because of its high frequency and concomitant risk of cardiovascular (CV)/cerebrovascular morbidity and mortality (Kearney et al., 2005; Lawes, et al., 2008). It is estimated to cause 7.5 million deaths that are 12·8% of the total number of deaths worldwide (Global Health Observatory 2018).

Globally, various epidemiological studies report that about 30% of patients with OSA have hypertension, (Bouloukaki et al., 2018; Lavie, et al., 2000; Marin et al., 2012; Mubarik et al., 2017) while in patients with
resistant hypertension the prevalence of OSA is reported to be 80% (Min et al., 2015; Muxfeldt et al., 2014).

Epidemiological studies from Asia have shown that the prevalence of OSA in patients with hypertension varies from 14–75% (Ip et al., 1999; Pensuksan et al., 2014; Shirani et al., 2016; Wali, et al., 2017). A number of studies from India have garnered data regarding the overall prevalence of OSA in general population (Kumar et al., 2006; Reddy et al., 2009; Sharma et al., 2010; Udwadia et al., 2004). However, there is insufficient data to determine the prevalence of OSA in patients with hypertension. This lack of epidemiological aspects confirming relation if any, of hypertension with OSA has remained an unmet research need. The current study investigates the prevalence of OSA in confirmed hypertensive cases and correlates the severity of hypertension and OSA in terms of Berlin and Epworth scores.

Methods

This cross-sectional study was conducted at the Department of General Medicine of a tertiary care hospital of India. The participants were prospectively selected for a period of six months. Patients 18 years and older, of both sexes, who came for consultation/treatment at the Department of General Medicine, with a known case of hypertension were enrolled for the study and a well-informed consent was taken from all the patients before enrollment in the study. Hypertension was categorized, as stage 1 (140-159/90-99 mm Hg) and stage 2 (≥160/100 mm Hg) based on the guidelines by the American Heart Association on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (Williams et al., 2018). Resistant Hypertension was defined as the failure to control clinic BP levels, despite the use of ≥3 antihypertensive drugs in optimal dosages, ideally including a diuretic, or achieving it with ≥4 drugs (Calhoun et al., 2008), while uncontrolled hypertension was defined as an office BP ≥140/90 mm Hg at the day of consultation (James et al., 2014). All patients, who consented to participate, were recruited by one attending physician. The patients were asked to complete a standardized questionnaire surveying the information regarding demographics and lifestyle factors (Table 1). In addition to this, the Berlin questionnaire (Tan et al., 2017) was used to determine the risk of developing OSA, dividing the patients into high and low-risk categories (Netzer et al., 1999). The Epworth sleepiness scale (ESS) was used to evaluate sleep propensity in patients. The scale covers the whole range of sleep propensities, from the highest to the lowest. ESS classified subjects into five groups based on the score: 0-5, Lower Normal Daytime Sleepiness; 6-10, Higher Normal Daytime Sleepiness; 11-12, Mild Excessive Daytime Sleepiness; 13-15, Moderate Excessive Daytime Sleepiness; 16-24, Severe Excessive Daytime Sleepiness (Johns, 1991). After the completion of questionnaires, measurement of BP, height, weight, waist circumference (WC), neck circumference (NC), and hip circumference, were taken. BP measurement was recorded using a mercury sphygmomanometer (Speider & Keller, Jungingen, Germany) and/or oscillometric devices, according to the recommendations of the American Heart Association Council on High Blood Pressure Research (Muntner et al., 2019). Height and weight measurements were obtained to calculate BMI and to categorize underweight (BMI<18 kg/m²), normal weight (18.5–24.9 kg/m²), overweight (25–29.9 kg/m²), class 1 obesity (30–34.9 kg/m²), class 2 obesity (35–39.9 kg/m²), and class 3- extreme obesity (≥40
kg/m$^2$) (World Health Organization, 2016). The normal cut-off value for NC was taken as 35·5 cm for men and 32 cm for women (Fink, 2016). WC was defined using the new International Diabetes Federation criteria for Asians: WC $\geq$90 cm for men and $\geq$80 cm for women (International Diabetes Federation, 2019). The normal cut-off value for NC was taken as 35·5 cm for men and 32 cm for women (Fink, 2016). WC was defined using the new International Diabetes Federation criteria for Asians: WC $\geq$90 cm for men and $\geq$80 cm for women (International Diabetes Federation, 2019). The normal cut-off value for NC was taken as 35·5 cm for men and 32 cm for women (Fink, 2016). WC was defined using the new International Diabetes Federation criteria for Asians: WC $\geq$90 cm for men and $\geq$80 cm for women (International Diabetes Federation, 2019). The ethical clearance for the study was obtained from the institutional review board of Government Medical College/SMHS under the investigation vide number: 108/ETH/GMC/ICM Dated 28/10/2017. A flow diagram depicting the number of subjects recruited at each step is shown in Figure 1.

A sample size of 504 patients was calculated based on the estimated prevalence of OSA of 40% (Senaratna et al., 2017) among case-patients, with a power of 90% and an $\alpha$ error of 5%. The statistical analysis was done using IBM SPSS (Statistical Package for the Social Sciences), V·20·0. (Armonk, NY: IBM Corp) software. Data is expressed as mean $\pm$ SD. The differences between means were compared using the Student t-test. Factors associated with high risk of OSA and excessive daytime sleepiness (EDS) were identified using the $\chi^2$ test in the univariate analysis. Significant variables from the $\chi^2$ test were then included in the multivariate logistic regression model for the assessment of the independent effect of individual factors. A p-value of $0.05$ was considered statistically significant.

### Results

Over a period of 6 months, 737 subjects were surveyed, of which 504 (69%) responded and completed the study. In this sample, men and women were nearly equally distributed (male 253: female 251). The mean age of the sample was 56±11 years. On the basis of the Berlin questionnaire, the study population was divided into two groups according to patients exhibiting high risk and low-risk of OSA. High risk of OSA, as per the Berlin questionnaire, was present in 23·8% (n=120) of the population (Figure 3) and the severe excessive daytime sleepiness, according to the Epworth Sleepiness Scale, was present in 32·5% (n=39) participants of the high-risk group. The high-risk of OSA was present in 43.3% males and 56.7% females while low-risk was present in 52.3% males and 47.7% females (p=0.05) (Table 2).

The anthropometric indices, including BMI, NC, WC, were significantly higher in patients with high-risk of OSA (p<0·001; 95% CI for all comparisons). The mean BMI for the patients with high-risk of OSA was 28·75 $\pm$ 5·4 kg/m$^2$ and 25·51 $\pm$ 4·5 kg/m$^2$ (p<0·001; 95% CI) for the low-risk group. However, the mean WHR for the two groups was clinically insignificant. About 97% of patients in the high-risk group had abnormal WHR while only 4·7% of the low-risk group had normal WHR (p=0·295; 95% CI). The descriptive statistical analysis of various anthropometric parameters in study patients is given in Table 2.

The mean systolic and diastolic BP measurements were significantly higher in patients with a high risk of OSA (p<0·05; 95% CI) (Figure 4). Uncontrolled hypertension was present in 50% (n=60) of patients with high-risk for OSA while 57·6% (n=221) of patients had controlled hypertension in low-risk group (p=0·146; 95% CI). Resistant hypertension was present in 3·3% (n=4) subjects in high-risk OSA category while 99·5% (n=382) subjects in low-risk group had non-resistant hypertension (p<0·05; 95% CI). The Epworth score of
>10 was found in 62.5% (n=75) patients with high-risk for OSA and <10 was found in 86.1% (n=331) among low-risk group (p<0.001; 95% CI). The patients with high-risk for OSA tended to use more medication than the low-risk group, with 7.5% of patients in the former group using three drugs simultaneously while only 2.08% in the latter group used triple therapy (p<0.05; 95% CI).

The most notable clinical variables in univariate analyses associated with high-risk of OSA were BP, sleepiness, hypertension control-status, resistant hypertension, diabetes, and obesity. The most common co-morbidities associated with hypertension were type 2 diabetes mellitus (23.2%), subclinical hypothyroidism (9.5%), dyslipidemia (4%), obesity (4%), and non-alcoholic fatty liver disease (2.4%) (Table 1). The high-risk group presented with disturbed sleep (29.2%), high daytime somnolence (32.5%), high fatigue/lethargy (46.7%), and loud snoring (84.2%) while these parameters were relatively normal in the low-risk group (p<0.001; 95% CI). The clinical parameters of study patients are summarized in Table 3.

Discussion

The present study is a large data set furnishing information regarding the prevalence of obstructive sleep apnoea in patients with hypertension in India. The target population was identified on the basis of physician detected hypertension and the patient data was collected by a standardized protocol on snoring, daytime sleepiness, BP, and other features associated with OSA.

Our study demonstrates that OSA is widely prevalent in patients with hypertension. Based on the standard Berlin questionnaire, 24% of the test population was found to be at high risk for OSA (i.e., 1 in every 4 hypertensive individuals). Our study is in accordance with studies by Peppard and colleagues who identified 24-28% prevalence of OSA in hypertension (Peppard et al., 2013).

The prevalence of daytime sleepiness in this sample was 62.5% by the Epworth scale result above 10 points. This prevalence in our sample is in agreement with the prevalence identified in a previous report of patients with hypertension (Ngahane et al., 2015). In that study, the authors identified the prevalence of excessive daytime sleepiness to be 62.78% (95% CI 58.08 to 67.47).

The overall mean age of the high risk for OSA respondents was 53.4 ± 9.02 years. The prevalence of OSA was highest between 51-60 years of age and this risk increased exponentially from 0.8% at ≤ 30 years of age to 41.7% at 51-60 years of age (p<0.001) (Figure 2). This finding is in agreement with the previous studies demonstrating the effect of age on OSA status (Deng et al., 2014; Ip et al., 1999).

The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recognizes both the independent role of OSA in the development of hypertension and OSA in association with obesity (Chobanian, 2003). In our study, patients with high-risk of OSA had significantly higher BMI, WC, WHR, and NC values statistically as compared to the patients with low-risk of OSA (Figure 3). All of the anthropometric indices (NC, WC, and BMI) were significantly correlated with the risk of OSA. These results are similar to those of previous studies. Kang et al. reported that NC [95%
CI; p<0·001], WC (95% CI; p<0·001), and BMI (95% CI; p<0·001) were significantly associated with the presence of OSA (Kang et al., 2014). Hiestand and colleagues reported that among obese subjects (BMI ≥30kg/m²), 59% of subjects were at high risk of OSA (Hiestand et al., 2006). In our study, only 37·5% of subjects were at high risk of OSA among obese patients (BMI ≥30 kg/m²).

In a study by Endeshaw and colleagues the mean BP values among older adults with sleep-disordered breathing were 133±16 and 71±8 mm Hg for systolic and diastolic BP, respectively (p < 0·001) (Endeshaw et al., 2009). In our study, the average systolic and diastolic BP was 133·52 ± 17·503 and 84·37 ± 7·425 mm Hg (Figure 4).

In our study, OSA was found to be strongly associated with resistant hypertension. Though our sample size was not large enough to justify a meaningful conclusion on this, another case-control study by Gonçalves et al. reported that OSA is a strong independent risk factor for resistant hypertension (Gonçalves et al., 2007). This study represents an advanced approach in the understanding of the risk factors of hypertension and gives an insight into the prevalence of high-risk of OSA in patients with hypertension. The Berlin Questionnaire, used in our study, is a validated method that has been used widely to identify individuals who are at risk for OSA (Gus et al., 2008). Our assessment of excessive daytime sleepiness was based on the ESS score, which is a well-tested international tool for the evaluation of daytime sleepiness (Boyes et al., 2017). With the increasing problem of hypertension, the impact of undetected or under-diagnosed OSA as a healthcare burden cannot be undermined. Therefore, this study can help reduce CV outcomes and healthcare costs of a rigorous anti-hypertensive regimen by treating the underlying cause.

There are a few limitations in our study that need to be considered. Firstly, the collection of data has been from a single tertiary care hospital for a limited period of time yielding a small size of the patient population. Secondly, the Berlin Questionnaire was used to identify high risk for OSA instead of polysomnography which is the gold-standard test for the diagnosis of OSA in clinical settings (Pang et al., 2006). However, it is complex, expensive, time-consuming, and is not available for the general population in India. The Berlin Questionnaire is a reliable tool and has been found to generate comparable results to that of polysomnography, yet there is a possibility of variation in the precision of results (Amra et al., 2018). We believe further studies using overnight polysomnography are warranted to exhaustively elucidate the bidirectional association between OSA and hypertension from different healthcare facilities of the state.

**Conclusion**

OSA is one of the most underdiagnosed and overlooked conditions in the health care system. The screening of OSA must be done in every suspected case, such as uncontrolled BP, unexplained hypertension, resistant hypertension, and obese patients. Our study concludes that nearly one in every four hypertensive patients is at high risk of OSA and most of them are obese and have a large neck circumference. Therefore, patients who feel very dizzy, fatigued and lethargic during the day should
consult the physician, while the health-care personnel involved in the management of hypertensive patients should screen OSA and EDS and consider life-style modifications in patients who are at a high risk of developing OSA. The current study strengthens the acceptance of OSA as a risk factor for hypertension, in terms of essential hypertension and resistant hypertension. The results of the study suggest new and possibly modifiable variables that can be targeted in future trials focusing on hypertensive medication.

**Abbreviations**

BMI: Body Mass Index
BP: Blood Pressure
ESS: Epworth Sleepiness Scale
HC: Hip Circumference
mm Hg: millimeters of Mercury
NC: Neck Circumference
OSA: Obstructive Sleep Apnoea
SPSS: Statistical Package for the Social Sciences
WC: Waist Circumference
WHR: Waist-to-hip ratio

**Declarations**

**Ethical approval**

Ethical approval was obtained from the Institutional Ethics Committee of Government Medical College/Shri Maharaja Hari Singh (IEC-GMC/SMHS), in accordance with Indian Council of Medical Research (ICMR) guidelines. Institutional Ethical Registration Number: 108/ETH/GMC/ICM Dated 28/10/2017.

**Consent to participate**
A well informed written as well as verbal consent was obtained from all individual participants included in the study.

**Consent for publication**

Not applicable

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Competing Interests**

The authors declare that they have no competing interests

**Funding/support**

This research did not receive grant of any sort from any funding agencies in the public, commercial, or not-for-profit sectors to ensure that there is no bias in collection or interpretation of data, so any role by them in the study design or data collection or analysis does not arise.

**Author's Contribution**

GNB and MT initiated the idea and designed the study protocol. OK performed the research at the hospital under the active involvement of MT. GNB and MT supervised the overall work. GNB and OK drafted the manuscript. All authors contributed to the writing of the final manuscript and approved the final version.

**Acknowledgments**

The authors would like to acknowledge the statistical help provided by Dr. Inam-ul-Haq, Government Medical College, Srinagar, J&K.

**References**

1. Amra B, Rahmati B, Soltaninejad F, Feizi A. Screening Questionnaires for Obstructive Sleep Apnea: An Updated Systematic Review. Oman Med J 2018;33(3):184–92.

2. Berhard Fink. Neck Circumference: Its Usage in Medicine and Biology. Victor R Preedy (ed). Handbook of Anthropometry. New York: Springer; 2012. pp. 665.

3. Bouloukaki I, Steiropoulos P, Bonsignore M, Mcnicholas W, Hedner J, Grote L et al. Mild obstructive sleep apnoea (OSA) and arterial hypertension in the European Sleep Apnoea Database (ESADA) cohort study. Eur Respir J 2018;52(suppl 62).
4. Boyes J, Drakatos P, Jarrold I, Smith J, Steier J. The use of an online Epworth Sleepiness Scale to assess excessive daytime sleepiness. Sleep Breath 2017 May;21(2):333-40.

5. Bradley TD, Floras JS. Sleep apnea and heart failure: Part I: Obstructive sleep apnea. Circulation 2003 Apr 1;107(12):1671-8.

6. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD et al. Resistant hypertension: diagnosis, evaluation, and treatment: A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008 Jun;51(6):1403-19.

7. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec;42(6):1206-52.

8. Deng X, Gu W, Li Y, Liu M, Li Y, Gao X. Age-Group-Specific Associations between the Severity of Obstructive Sleep Apnea and Relevant Risk Factors in Male and Female Patients. PLoS ONE 2014 Sep 11;9(9):e107380.

9. Endeshaw YW, White WB, Kutner M, Ouslander JG, Bliwise DL. Sleep-Disordered Breathing and 24-Hour Blood Pressure Pattern Among Older Adults. J Gerontol A Biol Sci Med Sci 2009;64(2):280-285.

10. Global Health Observatory (GHO) data. Raised Blood Pressure. [Online]. 2018 [cited 2018 Feb 23];[6 screens]. Available from: URL:http://www.who.int/gho/ncd/risk_factors/blood_pressure_prevalence_text/en/

11. Gonçalves SC, Martinez D, Gus M, de Abreu-Silva EO, Bertoluci C, Dutra I et al. Obstructive Sleep Apnea and Resistant Hypertension : a case-control study. Chest 2007 Dec;132(6):1858-62.

12. Guilleminault C, Abad VC. Obstructive sleep apnea. Curr Treat Options Neurol 2004 Jul;6(4):309-17.

13. Gus M, Gonçalves SC, Martinez D, de Abreu Silva EO, Moreira LB, Fuchs SC et al. Risk for Obstructive Sleep Apnea by Berlin Questionnaire, but not daytime sleepiness, is associated with resistant hypertension : A case-control Study. Am J Hypertens 2008 Jul;21(7):832-5.

14. Hiestand DM, Britz P, Goldman M, Phillips B. Prevalence of Symptoms and Risk of Sleep Apnea in the US Population. Chest 2006;130(3):780-786.

15. International Diabetes Federation (IDF). The IDF consensus worldwide definition of the metabolic syndrome. [Online] [cited 2019 Feb 12]. Available from: URL:https://www.pitt.edu/~super1/Metabolic/IDF1.pdf

16. Ip M, Chung KF, Chan KN, Lam SP, Lee K. Previously Unrecognized Obstructive Sleep Apnea in Chinese Subjects With Essential Hypertension. Lung 1999 Nov;117(6):391–400.

17. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J et al. 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC). JAMA 2014 Feb 5;311(5):507-20.

18. Johns MW. A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale. Sleep 1991 Nov 1;14(6):540-5.
19. Kang HH, Kang JY, Ha JH, Lee J, Kim SK. The Associations between Anthropometric Indices and Obstructive Sleep Apnea in a Korean Population. 2014:1-12. doi:10.1371/journal.pone.0114463.
20. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005 Jan 15-21;365(9455):217-23.
21. Lavie P, Herer P, Hoffstein V. Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. BMJ 2000 Feb 19;320(7233):479-82.
22. Lawes C, Vander Hoorn S, Rodgers A, International Society of Hypertension. Global burden of blood pressure related disease, 2001. Lancet 2008 May 3;371(9623):1531-8.
23. Leung RT, Bradley DT. Sleep Apnea and Cardiovascular Disease. Am J Respir Crit Care Med 2001;164(12):2147-65.
24. Marin J, Agusti A, Villar I, Forner M, Nieto D, Carrizo SJ et al. Association between treated and untreated obstructive sleep apnea and risk of hypertension. JAMA 2012 May 23;307(2):2169-76.
25. Min HJ, Cho YJ, Kim CH, Kim DH, Kim HY, Choi JI et al. Clinical Features of Obstructive Sleep Apnea That Determine Its High Prevalence in Resistant Hypertension. Yonsei Mrd J 2015 Sep;56(5):1258-65.
26. Mubarik A, Burney W, Khan SA, Qasim M, Basit M, Hassan SM. Prevalence of Comorbidities in Obstructive Sleep Apnea Population Waiting for Bariatric Surgery. J Gen Emerg Med 2017 Sep 04; 2(6):32.
27. Muntner P, Shimbo D, Carey RM, Charleston JB, Gaillard T, Misra S et al. Measurement of Blood Pressure in Humans: A Scientific Statement From the American Heart Association. Hypertension 2019 Mar 4;73(5):e35-e66.
28. Muxfeldt ES, Margallo VS, Guimarães GM, Salles GF. Prevalence and associated factors of obstructive sleep apnea in patients with resistant hypertension. Am J Hypertens. 2014 Aug; 27(8):1069-78.
29. Netzer NC, Stooohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med 1999 Oct 5;131(7):485-91.
30. Ngahane BHM, Nganda MM, Dzudie A, Luma H, Kamdem F, Ngote HR et al. Prevalence and determinants of excessive daytime sleepiness in hypertensive patients: a cross-sectional study in Douala, Cameroon. BMJ Open 2015;5(7):e008339.
31. Pang KP, Terris DJ. Screening for obstructive sleep apnea: an evidence-based analysis. Am J Otolaryngol 2006 Mar-Apr;27(2):112–8.
32. Park JG, Ramar K, Olson EJ. Updates on definition, consequences, and management of obstructive sleep apnea. Mayo Clin Proc. 2011 Jun;86(6):549-54.
33. Pensuksan WC, Chen X, Lohsoonthorn V, Lertmaharir S, Gelave B, Williams MA. High Risk for Obstructive Sleep Apnea in Relation to Hypertension Among Southeast Asian Young Adults: Role of Obesity as an Effect Modifier. Am J Hypertens 2014 Feb;27(2):229–236.
34. Peppard PE, Terry Y, Jodi HB, Mari P, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol 2013 May 1;177(9):1006-14.
35. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep disordered breathing and hypertension. N Eng J Med 2000 May 11;342(19):1378-84.
36. Pien GW, Rosen IM, Fields BG. Fishman’s pulmonary diseases and disorders. Sleep apnea syndromes: central and obstructive sleep apnea. 5th ed. New York: McGraw-Hill Education; 2015.
37. Reddy EV, Kadhiravan T, Mishra HK, Sreenivas V, Handa KK, Sinha S et al. Prevalence and risk factors of obstructive sleep apnea among middle-aged urban Indians: A community-based study. Sleep Med 2009 Sep;10(8):913-8.
38. Senaratna CV, Perret JL, Lodge CJ, Lowe AJ, Campbell BE, Matheson MC et al. Prevalence of obstructive sleep apnea in the general population: A systematic review. Sleep Med Rev 2017 Aug;34:70-81.
39. Sharma SK, Kumpawat S, Banga A, Goel A. Prevalence and Risk Factors of Obstructive Sleep Apnea Syndrome in a Population of Delhi, India. Chest 2006 Jul;130(1):149-156.
40. Sharma SK, Ahluwalia G. Epidemiology of adult obstructive sleep apnoea syndrome in India. Indian J Med Res 2009 Feb;131:171-175.
41. Shirani G, Morovati SP, Shamshiri AR, Nouri M, Givi NE, Farhadi M. Prevalence of Cardiovascular Disorders in Iranian Patients Suffering from Obstructive Sleep Apnea. J Dent (Tehran) 2016 Jun;13(3):151–156.
42. Tan A, Yin JD, Tan LW, van Dam RM, Cheung YY, Lee CH. Using the Berlin Questionnaire to predict obstructive sleep apnea in the general population. J Clin Sleep Med 2017 Mar 15;13(3):427-32.
43. Udwadia ZF, Doshi AV, Lonkar SG, Singh CI. Prevalence of Sleep-disordered Breathing and Sleep Apnea in Middle-aged Urban Indian Men. Am J Respir Crit Care Med 2004 Jan 15;169(2):168–173.
44. Wali S, Abalkhail O, Krayem A. Prevalence and risk factors of obstructive sleep apnea syndrome in a Saudi Arabian population. Ann Thorac Med 2017;12(2):88–94.
45. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J 2018;39:3021-3104.
46. World Health Organization. Global Database on Body Mass Index. [Online]. 2016 [cited 2019 Jan 28]. Available from: URL:http://www.assessmentpsychology.com/icbmi.htm

Tables

Table 1: Baseline demographic and clinical characteristics of the study patients.
| Variable                                | Low Risk Subjects |                  | High Risk Subjects |                  |
|-----------------------------------------|-------------------|------------------|--------------------|------------------|
| N=384                                   |                   |                  | N=120              |                  |
| Age – yrs                               | 56.5 ± 12.4       |                  | 53.4 ± 9.02        |                  |
| Height – m                              | 1.60 ± 0.092      |                  | 1.61 ± 0.099       |                  |
| Body Weight – kg                        | 65.19 ± 11.085    |                  | 73.63 ± 14.31      |                  |
| BMI – kg/m²                             | 25.5 ± 4.57       |                  | 28.75 ± 5.42       |                  |
| Neck Circumference – cm                 | 35.45 ± 2.652     |                  | 37.41 ± 3.396      |                  |
| Waist Circumference – cm                | 98.75 ± 10.87     |                  | 105.90 ± 11.28     |                  |
| Hip Circumference – cm                  | 98.85 ± 8.59      |                  | 104.25 ± 9.99      |                  |
| Waist to Hip Ratio                      | 0.99 ± 0.080      |                  | 1.01 ± 0.065       |                  |
| **Epworth Sleepiness Score**            |                   |                  |                    |                  |
| Lower Normal Daytime Sleepiness         | 3.45 ± 1.091      |                  | 3.375 ± 1.025      |                  |
| Higher Normal Daytime Sleepiness        | 7.73 ± 1.330      |                  | 7.94 ± 1.279       |                  |
| Mild Excessive Daytime Sleepiness       | 11.32 ± 0.476     |                  | 11.77 ± 0.437      |                  |
| Moderate Excessive Daytime Sleepiness   | 13.75 ± 0.808     |                  | 13.85 ± 0.834      |                  |
| Severe Excessive Daytime Sleepiness     | 17.45 ± 2.018     |                  | 18 ± 1.805         |                  |
| **Total Therapy Used**                  | 1.27 ± 0.497      |                  | 1.44 ± 0.631       |                  |
| **Co-morbidities (No.)**                |                   |                  |                    |                  |
| Diabetes                                | 84                |                  | 33                 |                  |
| Sub-Clinical Hypothyroidism             | 31                |                  | 17                 |                  |
| Dyslipidemia                            | 12                |                  | 8                  |                  |
| Obesity                                 | 12                |                  | 8                  |                  |
| NAFLD                                   | 6                 |                  | 6                  |                  |
| Others                                  | 140               |                  | 26                 |                  |

Data is reported as number (percentage) or mean ± standard deviation.

BMI indicates body mass index.
Table 2: Descriptive statistical analysis of various anthropometric parameters in study patients.
| Parameter               | Low Risk | High Risk | Total | p-value |
|-------------------------|----------|-----------|-------|---------|
| **Sex**                 |          |           |       |         |
| Male                    |          |           |       |         |
| Count                   | 201      | 52        | 253   | 0.05    |
| % within Berlin category| 52.3%    | 43.3%     | 50.2% |         |
| Female                  |          |           |       |         |
| Count                   | 183      | 68        | 251   |         |
| % within Berlin category| 47.7%    | 56.7%     | 49.8% |         |
| **BMI**                 |          |           |       |         |
| <30kg/m²                |          |           |       |         |
| Count                   | 327      | 75        | 402   | 0.001   |
| % within Berlin category| 85.1%    | 19.5%     | 79.8% |         |
| ≥30kg/m²                |          |           |       |         |
| Count                   | 57       | 45        | 102   |         |
| % within Berlin category| 14.8%    | 37.5%     | 20.2% |         |
| **Neck Circumference $**|          |           |       |         |
| Normal                  |          |           |       |         |
| Count                   | 134      | 14        | 148   | 0.001   |
| % within Berlin category| 34.9%    | 11.7%     | 29.4% |         |
| Abnormal                |          |           |       |         |
| Count                   | 250      | 106       | 356   |         |
| % within Berlin category| 65.1%    | 88.3%     | 70.6% |         |
| **Waist Circumference #**|         |           |       |         |
| Normal                  |          |           |       |         |
| Count                   | 104      | 12        | 116   | 0.001   |
| % within Berlin category| 27.1%    | 10.0%     | 23.0% |         |
| Abnormal                |          |           |       |         |
| Count                   | 280      | 108       | 388   |         |
| % within Berlin category| 72.9%    | 90.0%     | 77.0% |         |
| **WHR €**               |          |           |       |         |
| Normal                  |          |           |       |         |
| Count                   | 18       | 3         | 21    | 0.295   |
| % within Berlin category| 4.7%     | 2.5%      | 4.2%  |         |
| Abnormal                |          |           |       |         |
| Count                   | 366      | 117       | 483   |         |
| % within Berlin category| 95.3%    | 97.5%     | 95.8% |         |

$ The cut-off for neck circumference of male and female were taken as 35.5 and 32 cm respectively.
The WHO standards put cut-off for waist circumference for male and female at 94 and 80 cm respectively.

A normal waist-to-hip ratio is taken as 0.88 and 0.81 for male and female respectively.

**Table 3**: Descriptive statistical analysis of various clinical parameters in study patients.
| Parameter                          | Low Risk       | High Risk       | Total | p-value |
|-----------------------------------|----------------|-----------------|-------|---------|
| **Blood Pressure (mm Hg)**        |                |                 |       |         |
| Systolic                          | 130.21 ± 17.244 | 133.52 ± 17.503 | <0.05 |         |
| Diastolic                         | 82.69 ± 9.531  | 84.37 ± 7.425   |       |         |
| **Hypertension Control**          |                |                 |       |         |
| Controlled                        | Count          | 221             | 60    | 281     | 0.146  |
| % within Berlin category          | 57.6%          | 50.0%           | 55.8% |         |
| Uncontrolled                      | Count          | 163             | 60    | 223     |
| % within Berlin category          | 42.4%          | 50.0%           | 44.2% |         |
| **Resistant Hypertension**        |                |                 |       |         |
| Non-Resistant hypertension        | Count          | 382             | 116   | 498     | <0.05  |
| % within Berlin category          | 99.5%          | 96.7%           | 98.8% |         |
| Resistant hypertension            | Count          | 2               | 4     | 6       |
| % within Berlin category          | 0.5%           | 3.3%            | 1.2%  |         |
| **Epworth Score**                 |                |                 |       |         |
| 0-5                               | Count          | 205             | 16    | 221     | <0.001 |
| % within Berlin category          | 53.4%          | 13.3%           | 43.8% |         |
| 6-10                              | Count          | 126             | 29    | 155     |
| % within Berlin category          | 32.8%          | 24.2%           | 30.8% |         |
| 11-12                             | Count          | 25              | 17    | 42      |
| % within Berlin category          | 6.5%           | 14.2%           | 8.3%  |         |
| 13-15                             | Count          | 17              | 19    | 36      |
| % within Berlin category          | 4.4%           | 15.8%           | 7.1%  |         |
| 16-24                             | Count          | 11              | 39    | 50      |
| Therapy       | Count | % within Berlin category | 2.9% | 32.5% | 9.9% |
|--------------|-------|--------------------------|------|-------|------|
| Off Therapy  |       |                          | 1    | 0     | 1    | <0.05|
|              | % within Berlin category | 0.26% | 0.0% | 0.26% |
| Monotherapy  |       |                          | 284  | 77    | 361  |
|              | % within Berlin category | 73.9% | 64.1% | 71.6% |
| Double Therapy |     |                          | 91   | 34    | 125  |
|              | % within Berlin category | 23.6% | 28.3% | 24.8% |
| Triple Therapy |     |                          | 8    | 9     | 17   |
|              | % within Berlin category | 2.08 | 7.5% | 3.37% |

**Figures**
Figure 1

Flowchart of the screened patients.

Figure 2

Chart showing the percent of patients by age (yrs) and risk level.
Comparison between age and the risk of Obstructive Sleep Apnoea.

Figure 3

Comparison between BMI and the risk of Obstructive Sleep Apnoea.
Comparison of SBP and DBP in high and low risk subjects.